{"id":390396,"date":"2019-06-20T00:00:00","date_gmt":"2019-06-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0005-2018-biopharma-non-small-cell-lung-cancer-current-treatment-physician-insights-us-2018\/"},"modified":"2026-04-14T10:25:40","modified_gmt":"2026-04-14T10:25:40","slug":"cutron0005-2018-biopharma-non-small-cell-lung-cancer-current-treatment-physician-insights-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0005-2018-biopharma-non-small-cell-lung-cancer-current-treatment-physician-insights-us-2018\/","title":{"rendered":"Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2018"},"content":{"rendered":"<p>The treatment landscape for <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include the approvals of Alunbrig for <em><abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr><\/em>-positive metastatic <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>,Tafinlar plus Mekinist for <em><abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr><\/em>-mutation-positive <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>, and Imfinzi for unresectable stage III <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> as well as the label expansion of Keytruda in combination with chemotherapy as a first-line regimen for metastatic nonsquamous patients. Our primary research provides insight into the current use of approved therapies for <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> in the United States and uncovers key factors that influence medical oncologists\u2019 prescribing decisions in this highly dynamic indication.<\/p>\n","protected":false},"template":"","class_list":["post-390396","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390396\/revisions"}],"predecessor-version":[{"id":393521,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390396\/revisions\/393521"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}